某院2013年至2015年慢性乙型肝炎抗病毒药物应用分析

Application of Antiviral Drugs for Hepatitis B in a Hospital from 2013 to 2015

目的探讨医院2013年至2015年慢性乙型肝炎抗病毒药物应用的情况及趋势。方法统计分析医院2013年至2015年慢性乙型肝炎抗病毒药物的销售金额、用药频度(DDDs)、日均费用(DDC)等数据。结果医院慢性乙型肝炎抗病毒药物的销售金额呈逐年上升趋势,3年间,恩替卡韦用量逐年增加且增幅均较大,销售金额、DDDs均排名第1;其次为阿德福韦酯片,而干扰素销售金额无明显变化。结论核苷酸类似物在慢性乙型肝炎抗病毒药物的临床使用中占主导地位,且临床医生更倾向于选择其中的恩替卡韦。长期应用相关药物或联合应用时,需监测患者乙型肝炎病毒耐药性及不良反应,从而实现个体化治疗。

Objective To investigate the application and trend of antiviral drugs for hepaitis B in the hospital from 2013 to 2015. Methods The total sales amount,DDDs,DDC of the antiviral drugs for hepaitis B in our hospital from 2013 to 2015 were ana- lyzed statistically. Results The sales amount of antiviral drugs for hepaitis B increased annually. Among the 3 years, the usage amount of Entecavir increased rapidly, and both the sale amount and DDDs ranked the first place, the Adefovir Tablet ranked next. The sales amount of interferon did not change significantly. Conclusion Necleoside analogues takes the dominant place in clinical Use among the antiviral drugs for hepaitis B, but clinicians preferred to use Entecavir. For the long time of nucleoside analogues or combined use, the drug tolerance to hepatitis B virus and the adverse reactions should be monitored to achieve the aim of differentiated treatment method for individuals.